Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Первичный энурез у взрослых: патогенез, клиническое течение и современные подходы к лечению
Первичный энурез у взрослых: патогенез, клиническое течение и современные подходы к лечению
Кузьмин И.В. Первичный энурез у взрослых: патогенез, клиническое течение и современные подходы к лечению. Consilium Medicum. 2022;24(10):753–758. DOI: 10.26442/20751753.2022.10.201947
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье приведены современные данные относительно эпидемиологии, классификации, патогенеза, факторов риска, диагностики, а также особенностей клинического течения первичного энуреза у взрослых. Подробно описаны основные методы лечения больных первичным энурезом. Показано, что при лечении данной категории больных ведущее значение придается применению синтетического аналога антидиуретического гормона десмопрессина. Представлен подробный анализ фармакологических свойств и клинического использования десмопрессина у больных первичным энурезом. Показаны преимущества назначения сублингвальной формы десмопрессина, обеспечивающей высокую эффективность и хорошую переносимость терапии.
Ключевые слова: первичный энурез, десмопрессин, антидиуретический гормон, ночное недержание мочи
A detailed analysis of the pharmacological properties and clinical use of desmopressin in patients with primary enuresis is presented. The advantages of prescribing a sublingual form of desmopressin, which ensures its high efficiency and good tolerability of therapy.
Keywords: primary enuresis, desmopressin, antidiuretic hormone, bedwetting
Ключевые слова: первичный энурез, десмопрессин, антидиуретический гормон, ночное недержание мочи
________________________________________________
A detailed analysis of the pharmacological properties and clinical use of desmopressin in patients with primary enuresis is presented. The advantages of prescribing a sublingual form of desmopressin, which ensures its high efficiency and good tolerability of therapy.
Keywords: primary enuresis, desmopressin, antidiuretic hormone, bedwetting
Полный текст
Список литературы
1. Nevéus T, von Gontard A, Hoebeke P, et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Report fr om the Standardisation Committee of the International Children’s Continence Society. J Urol. 2006;176(1):314-24. DOI:10.1016/S0022-5347(06)00305-3
2. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol. 2001;165(6Pt. 1):1914-7. DOI:10.1097/00005392-200106000-00017
3. Гусева Н.Б., Никитин С.С., Корсунский А.А., и др. Результаты многоцентрового исследования по диагностике немоносимптомного энуреза у детей в различных регионах РФ. Педиатрия. 2019;98(2):107-12 [Guseva NB, Nikitin SS, Korsunskiy AA, et al. Results of a multicenter study on the diagnosis of nonmonosymptomatic enuresis in children in various regions of the Russian Federation. Pediatria. 2019;98(2):107-12 (in Russian)]. DOI:10.24110/0031-403X-2019-98-2-107-112
4. Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol. 2002;36(5):354-62. DOI:10.1080/003655902320783863
5. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. Int J Clin Pract. 2009;63(4):568-73. DOI:10.1111/j.1742-1241.2008.01974.x
6. Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int. 2004;93(3):341-5. DOI:10.1111/j.1464-410x.2003.04612.x
7. Никитин С.С., Гусева Н.Б., Колодяжная А.В., и др. Enuresis nocturna у детей и подростков: обзор современной литературы и перспективы лечения с использованием десмопрессина. Педиатрия им. Г.Н. Сперанского. 2020;99(3):265-27 [Nikitin SS, Guseva NB, Kolodyazhnaya AV, et al. Enuresis nocturna in children and adolescents: a review of contemporary literature and treatment perspectives using desmopressin. Pediatria n.a. GN. Speransky. 2020;99(3):265-70 (in Russian)].
DOI:10.24110/0031-403X-2020-99-3-265-270
8. Levine A. Enuresis in the navy. Am J Psychiatry. 1943;100:320-5.
9. Hirasing RA, van Leerdam FJ, Bolk-Bennink L, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 1997;31(6):533-6. DOI:10.3109/00365599709030657
10. Baek M, Park K, Lee HE, et al. Korean Children's Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: population based cross sectional study. J Korean Med Sci. 2013;28(7):1065-70. DOI:10.3346/jkms.2013.28.7.1065
11. Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315-20. DOI:10.1007/s00192-016-3099-0
12. Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Wh ere is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43(4):401-6. DOI:10.1097/WON.0000000000000234
13. Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down Syndrome. Neurourol Urodyn. 2017;36(6):1550-6. DOI:10.1002/nau.23146
14. Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8(3):217-22. DOI:10.1007/s11884-013-0193-8
15. Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9(2):84-9. DOI:10.1007/s11884-014-0237-8
16. Akhavizadegan H, Locke JA, Stothers L, Kavanagh A. A comprehensive review of adult enuresis. Can Urol Assoc J. 2018;13(8):282-7. DOI:10.5489/cuaj.5485
17. Rittig S, Lassen Schaumburg H, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179(6):2389-95. DOI:10.1016/j.juro.2008.01.171
18. Бирюкова Е.В., Шинкин М.В. Центральный несахарный диабет: этиопатогенез, подходы к диагностике и лечению. Эффективная фармакотерапия. 2021;17(26):38-48 [Biryukova YeV, Shinkin MV. Central Diabetes Insipidus: Etiopathogenesis, Approaches to Diagnosis and Treatment. Effective Pharmacotherapy. 2021;17(26):38-48 (in Russian)]. DOI:10.33978/2307-3586-2021-17-26-38-48
19. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021-5. DOI:10.1097/01.ju.0000136203.76320.f6
20. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. DOI:10.1016/S0090-4295(02)02243-4
21. Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Expert Opin Pharmacother. 2018;19(3):291-8. DOI:10.1080/14656566.2018.1429406
22. Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23(2):175-82. DOI:10.1097/GME.0000000000000517
23. Шорманов И.С., Соловьев А.С., Тюзиков И.А., Куликов С.В. Анатомо-физиологические и патофизиологические особенности нижних мочевых путей в гендерном и возрастном аспектах. Урологические ведомости. 2021;11(3):241-56 [Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St-Petersburg). 2021;11(3):241-56 (in Russian)]. DOI:10.17816/uroved70710
24. Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы. Урологические ведомости. 2022;12(2):127-35 [Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35 (in Russian)]. DOI:10.17816/uroved108475
25. Abeygunasekera AM, Jayasinghe RJ, Duminda MT, et al. Significance of recent onset nocturnal enuresis in adult men: a prospective study. Ceylon Med J. 2004;49(3):79-81. DOI:10.4038/cmj.v49i3.3244
26. Madhu CK, Hashim H, Enki D, Drake MJ. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36(1):188-91. DOI:10.1002/nau.22912
27. Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря. Дис. … д-ра мед. наук. СПб., 2007 [Kuz'min IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyria: Dis. … d-ra med. nauk. Saint Petersburg, 2007 (in Russian)].
28. D’Ancona CAL, de Moraes Lopes MHB, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31(5):634-6. DOI:10.1002/nau.21195
29. Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171(6Pt2):2595-8. DOI:10.1097/01.ju.0000112790.72612.0a
30. Katz EG, MacLachlan LS. Nocturnal Enuresis in the Adult. Curr Urol Rep. 2020;21(8):31. DOI:10.1007/s11934-020-00983-2
31. Lee D, Dillon BE, Lemack GE. Adult Onset Nocturnal Enuresis: Identifying Causes, Cofactors and Impact on Quality of Life. Low Urin Tract Symptoms. 2018;10(3):292-6. DOI:10.1111/luts.12183
32. Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. 2019;133:24-33. DOI:10.1016/j.urology.2019.09.022
33. Sinha R, Raut S. Management of nocturnal enuresis – myths and facts. World J Nephrol. 2016;5(4):328-38. DOI:10.5527/wjn.v5.i4.32
34. Läckgren G, Hjälmås K, van Gool J, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999;88(6):679-90. DOI:10.1080/08035259950169396
35. Yucel S, Kutlu O, Kukul E, Baykara M. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64(5):1020-5. DOI:10.1016/j.urology.2004.06.067
36. Vandersteen DR, Husmann DA. Treatment of primary nocturnal enuresis persisting into adulthood. J Urol. 1999;161(1):90-2. DOI:10.1016/S0022-5347(01)62073-1
37. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009;74(4):915-9. DOI:10.1016/j.urology.2009.05.033
38. Neveus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. DOI:10.1007/s00467-011-1762-8
39. Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты. РМЖ. Медицинское обозрение. 2021;5(5):273-9 [Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian)].
DOI:10.32364/2587-6821-2021-5-5-273-279
40. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;1:120-5 [Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;1:120-5 (In Russian)]. DOI:10.18565/urology.2021.1.120-125
41. Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты. Урологические ведомости. 2020;10(2):163-71 [Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St-Petersburg). 2020;10(2):163-71 (in Russian)]. DOI:10.17816/uroved102163-171
42. Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты. Клиническая геронтология. 2021;27(11-12):21-34 [Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21-34 (in Russian)].
DOI:10.26347/1607-2499202111-12021-034
43. Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10(10):CD012059. DOI:10.1002/14651858.CD012059.pub2
44. F-MELT® – система вспомогательных веществ для производства таблеток, диспергируемых в ротовой полости (ODT). Фармацевтическая отрасль. 2015;6(53):68-9 [F-MELT® – sistema vspomogatel'nykh veshchestv dlia proizvodstva tabletok, dispergiruemykh v rotovoi polosti (ODT). Farmatsevticheskaia otrasl'. 2015;6(53):68-9 (in Russian)].
45. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-60. DOI:10.1111/j.1742-1241.2007.01493.x
46. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction. J Urol. 2011;185(6):2308-13. DOI:10.1016/j.juro.2011.02.039
47. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-11. DOI:10.1177/0091270006291838
48. Vande Walle JGJ, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97(3):603-9. DOI:10.1111/j.1464-410X.2006.05999.x
49. Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235-42. DOI:10.1007/s00431-013-1992-9
50. Проспективное открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем®, таблетки подъязычные 240 мкг (ЗАО «Канонфарма продакшн», Россия), и Минирин®, таблетки подъязычные 240 мкг («Ферринг АГ», Швейцария) у здоровых добровольцев после однократного приема натощак. Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Ссылка активна на 01.11.2022 [Prospektivnoe otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem®, tabletki pod"iazychnye 240 mkg (ZAO «Kanonfarma prodakshn», Rossiia) i Minirin®, tabletki pod"iazychnye 240 mkg («Ferring AG», Shveitsariia) u zdorovykh dobrovol'tsev posle odnokratnogo priema natoshchak Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Accessed: 01.11.2022 (in Russian)].
51. Открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем® таблетки, 0,2 мг (ЗАО «Канонфарма Продакшн», Россия), и Минирин® таблетки, 0,2 мг («Ферринг АБ», Швеция). Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Ссылка активна на 01.11.2022 [Otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem® tabletki, 0,2 mg (ZAO «Kanonfarma Prodakshn», Rossiia), i Minirin® tabletki, 0,2 mg («Ferring AB», Shvetsiia). Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Accessed: 01.11.2022 (in Russian)].
2. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol. 2001;165(6Pt. 1):1914-7. DOI:10.1097/00005392-200106000-00017
3. Guseva NB, Nikitin SS, Korsunskiy AA, et al. Results of a multicenter study on the diagnosis of nonmonosymptomatic enuresis in children in various regions of the Russian Federation. Pediatria. 2019;98(2):107-12 (in Russian). DOI:10.24110/0031-403X-2019-98-2-107-112
4. Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol. 2002;36(5):354-62. DOI:10.1080/003655902320783863
5. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. Int J Clin Pract. 2009;63(4):568-73. DOI:10.1111/j.1742-1241.2008.01974.x
6. Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int. 2004;93(3):341-5. DOI:10.1111/j.1464-410x.2003.04612.x
7. Nikitin SS, Guseva NB, Kolodyazhnaya AV, et al. Enuresis nocturna in children and adolescents: a review of contemporary literature and treatment perspectives using desmopressin. Pediatria n.a. GN. Speransky. 2020;99(3):265-70 (in Russian). DOI:10.24110/0031-403X-2020-99-3-265-270
8. Levine A. Enuresis in the navy. Am J Psychiatry. 1943;100:320-5.
9. Hirasing RA, van Leerdam FJ, Bolk-Bennink L, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 1997;31(6):533-6. DOI:10.3109/00365599709030657
10. Baek M, Park K, Lee HE, et al. Korean Children's Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: population based cross sectional study. J Korean Med Sci. 2013;28(7):1065-70. DOI:10.3346/jkms.2013.28.7.1065
11. Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315-20. DOI:10.1007/s00192-016-3099-0
12. Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Wh ere is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43(4):401-6. DOI:10.1097/WON.0000000000000234
13. Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down Syndrome. Neurourol Urodyn. 2017;36(6):1550-6. DOI:10.1002/nau.23146
14. Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8(3):217-22. DOI:10.1007/s11884-013-0193-8
15. Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9(2):84-9. DOI:10.1007/s11884-014-0237-8
16. Akhavizadegan H, Locke JA, Stothers L, Kavanagh A. A comprehensive review of adult enuresis. Can Urol Assoc J. 2018;13(8):282-7. DOI:10.5489/cuaj.5485
17. Rittig S, Lassen Schaumburg H, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179(6):2389-95. DOI:10.1016/j.juro.2008.01.171
18. Biryukova YeV, Shinkin MV. Central Diabetes Insipidus: Etiopathogenesis, Approaches to Diagnosis and Treatment. Effective Pharmacotherapy. 2021;17(26):38-48 (in Russian). DOI:10.33978/2307-3586-2021-17-26-38-48
19. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021-5. DOI:10.1097/01.ju.0000136203.76320.f6
20. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. DOI:10.1016/S0090-4295(02)02243-4
21. Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Expert Opin Pharmacother. 2018;19(3):291-8. DOI:10.1080/14656566.2018.1429406
22. Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23(2):175-82. DOI:10.1097/GME.0000000000000517
23. Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St-Petersburg). 2021;11(3):241-56 (in Russian). DOI:10.17816/uroved70710
24. Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35 (in Russian). DOI:10.17816/uroved108475
25. Abeygunasekera AM, Jayasinghe RJ, Duminda MT, et al. Significance of recent onset nocturnal enuresis in adult men: a prospective study. Ceylon Med J. 2004;49(3):79-81. DOI:10.4038/cmj.v49i3.3244
26. Madhu CK, Hashim H, Enki D, Drake MJ. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36(1):188-91. DOI:10.1002/nau.22912
27. Kuz'min IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyria: Dis. … d-ra med. nauk. Saint Petersburg, 2007 (in Russian).
28. D’Ancona CAL, de Moraes Lopes MHB, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31(5):634-6. DOI:10.1002/nau.21195
29. Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171(6Pt2):2595-8. DOI:10.1097/01.ju.0000112790.72612.0a
30. Katz EG, MacLachlan LS. Nocturnal Enuresis in the Adult. Curr Urol Rep. 2020;21(8):31. DOI:10.1007/s11934-020-00983-2
31. Lee D, Dillon BE, Lemack GE. Adult Onset Nocturnal Enuresis: Identifying Causes, Cofactors and Impact on Quality of Life. Low Urin Tract Symptoms. 2018;10(3):292-6. DOI:10.1111/luts.12183
32. Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. 2019;133:24-33. DOI:10.1016/j.urology.2019.09.022
33. Sinha R, Raut S. Management of nocturnal enuresis – myths and facts. World J Nephrol. 2016;5(4):328-38. DOI:10.5527/wjn.v5.i4.32
34. Läckgren G, Hjälmås K, van Gool J, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999;88(6):679-90. DOI:10.1080/08035259950169396
35. Yucel S, Kutlu O, Kukul E, Baykara M. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64(5):1020-5. DOI:10.1016/j.urology.2004.06.067
36. Vandersteen DR, Husmann DA. Treatment of primary nocturnal enuresis persisting into adulthood. J Urol. 1999;161(1):90-2. DOI:10.1016/S0022-5347(01)62073-1
37. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009;74(4):915-9. DOI:10.1016/j.urology.2009.05.033
38. Neveus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. DOI:10.1007/s00467-011-1762-8
39. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian).
DOI:10.32364/2587-6821-2021-5-5-273-279
40. Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;1:120-5 (In Russian). DOI:10.18565/urology.2021.1.120-125
41. Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St-Petersburg). 2020;10(2):163-71 (in Russian). DOI:10.17816/uroved102163-171
42. Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21-34 (in Russian).DOI:10.26347/1607-2499202111-12021-034
43. Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10(10):CD012059. DOI:10.1002/14651858.CD012059.pub2
44. F-MELT® – sistema vspomogatel'nykh veshchestv dlia proizvodstva tabletok, dispergiruemykh v rotovoi polosti (ODT). Farmatsevticheskaia otrasl'. 2015;6(53):68-9 (in Russian).
45. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-60. DOI:10.1111/j.1742-1241.2007.01493.x
46. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction. J Urol. 2011;185(6):2308-13. DOI:10.1016/j.juro.2011.02.039
47. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-11. DOI:10.1177/0091270006291838
48. Vande Walle JGJ, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97(3):603-9. DOI:10.1111/j.1464-410X.2006.05999.x
49. Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235-42. DOI:10.1007/s00431-013-1992-9
50. Prospektivnoe otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem®, tabletki pod"iazychnye 240 mkg (ZAO «Kanonfarma prodakshn», Rossiia) i Minirin®, tabletki pod"iazychnye 240 mkg («Ferring AG», Shveitsariia) u zdorovykh dobrovol'tsev posle odnokratnogo priema natoshchak Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Accessed: 01.11.2022 (in Russian).
51. Otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem® tabletki, 0,2 mg (ZAO «Kanonfarma Prodakshn», Rossiia), i Minirin® tabletki, 0,2 mg («Ferring AB», Shvetsiia). Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Accessed: 01.11.2022 (in Russian).
2. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol. 2001;165(6Pt. 1):1914-7. DOI:10.1097/00005392-200106000-00017
3. Гусева Н.Б., Никитин С.С., Корсунский А.А., и др. Результаты многоцентрового исследования по диагностике немоносимптомного энуреза у детей в различных регионах РФ. Педиатрия. 2019;98(2):107-12 [Guseva NB, Nikitin SS, Korsunskiy AA, et al. Results of a multicenter study on the diagnosis of nonmonosymptomatic enuresis in children in various regions of the Russian Federation. Pediatria. 2019;98(2):107-12 (in Russian)]. DOI:10.24110/0031-403X-2019-98-2-107-112
4. Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol. 2002;36(5):354-62. DOI:10.1080/003655902320783863
5. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. Int J Clin Pract. 2009;63(4):568-73. DOI:10.1111/j.1742-1241.2008.01974.x
6. Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int. 2004;93(3):341-5. DOI:10.1111/j.1464-410x.2003.04612.x
7. Никитин С.С., Гусева Н.Б., Колодяжная А.В., и др. Enuresis nocturna у детей и подростков: обзор современной литературы и перспективы лечения с использованием десмопрессина. Педиатрия им. Г.Н. Сперанского. 2020;99(3):265-27 [Nikitin SS, Guseva NB, Kolodyazhnaya AV, et al. Enuresis nocturna in children and adolescents: a review of contemporary literature and treatment perspectives using desmopressin. Pediatria n.a. GN. Speransky. 2020;99(3):265-70 (in Russian)].
DOI:10.24110/0031-403X-2020-99-3-265-270
8. Levine A. Enuresis in the navy. Am J Psychiatry. 1943;100:320-5.
9. Hirasing RA, van Leerdam FJ, Bolk-Bennink L, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 1997;31(6):533-6. DOI:10.3109/00365599709030657
10. Baek M, Park K, Lee HE, et al. Korean Children's Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: population based cross sectional study. J Korean Med Sci. 2013;28(7):1065-70. DOI:10.3346/jkms.2013.28.7.1065
11. Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315-20. DOI:10.1007/s00192-016-3099-0
12. Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Wh ere is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43(4):401-6. DOI:10.1097/WON.0000000000000234
13. Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down Syndrome. Neurourol Urodyn. 2017;36(6):1550-6. DOI:10.1002/nau.23146
14. Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8(3):217-22. DOI:10.1007/s11884-013-0193-8
15. Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9(2):84-9. DOI:10.1007/s11884-014-0237-8
16. Akhavizadegan H, Locke JA, Stothers L, Kavanagh A. A comprehensive review of adult enuresis. Can Urol Assoc J. 2018;13(8):282-7. DOI:10.5489/cuaj.5485
17. Rittig S, Lassen Schaumburg H, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179(6):2389-95. DOI:10.1016/j.juro.2008.01.171
18. Бирюкова Е.В., Шинкин М.В. Центральный несахарный диабет: этиопатогенез, подходы к диагностике и лечению. Эффективная фармакотерапия. 2021;17(26):38-48 [Biryukova YeV, Shinkin MV. Central Diabetes Insipidus: Etiopathogenesis, Approaches to Diagnosis and Treatment. Effective Pharmacotherapy. 2021;17(26):38-48 (in Russian)]. DOI:10.33978/2307-3586-2021-17-26-38-48
19. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021-5. DOI:10.1097/01.ju.0000136203.76320.f6
20. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. DOI:10.1016/S0090-4295(02)02243-4
21. Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Expert Opin Pharmacother. 2018;19(3):291-8. DOI:10.1080/14656566.2018.1429406
22. Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23(2):175-82. DOI:10.1097/GME.0000000000000517
23. Шорманов И.С., Соловьев А.С., Тюзиков И.А., Куликов С.В. Анатомо-физиологические и патофизиологические особенности нижних мочевых путей в гендерном и возрастном аспектах. Урологические ведомости. 2021;11(3):241-56 [Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St-Petersburg). 2021;11(3):241-56 (in Russian)]. DOI:10.17816/uroved70710
24. Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы. Урологические ведомости. 2022;12(2):127-35 [Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35 (in Russian)]. DOI:10.17816/uroved108475
25. Abeygunasekera AM, Jayasinghe RJ, Duminda MT, et al. Significance of recent onset nocturnal enuresis in adult men: a prospective study. Ceylon Med J. 2004;49(3):79-81. DOI:10.4038/cmj.v49i3.3244
26. Madhu CK, Hashim H, Enki D, Drake MJ. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36(1):188-91. DOI:10.1002/nau.22912
27. Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря. Дис. … д-ра мед. наук. СПб., 2007 [Kuz'min IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyria: Dis. … d-ra med. nauk. Saint Petersburg, 2007 (in Russian)].
28. D’Ancona CAL, de Moraes Lopes MHB, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31(5):634-6. DOI:10.1002/nau.21195
29. Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171(6Pt2):2595-8. DOI:10.1097/01.ju.0000112790.72612.0a
30. Katz EG, MacLachlan LS. Nocturnal Enuresis in the Adult. Curr Urol Rep. 2020;21(8):31. DOI:10.1007/s11934-020-00983-2
31. Lee D, Dillon BE, Lemack GE. Adult Onset Nocturnal Enuresis: Identifying Causes, Cofactors and Impact on Quality of Life. Low Urin Tract Symptoms. 2018;10(3):292-6. DOI:10.1111/luts.12183
32. Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. 2019;133:24-33. DOI:10.1016/j.urology.2019.09.022
33. Sinha R, Raut S. Management of nocturnal enuresis – myths and facts. World J Nephrol. 2016;5(4):328-38. DOI:10.5527/wjn.v5.i4.32
34. Läckgren G, Hjälmås K, van Gool J, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999;88(6):679-90. DOI:10.1080/08035259950169396
35. Yucel S, Kutlu O, Kukul E, Baykara M. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64(5):1020-5. DOI:10.1016/j.urology.2004.06.067
36. Vandersteen DR, Husmann DA. Treatment of primary nocturnal enuresis persisting into adulthood. J Urol. 1999;161(1):90-2. DOI:10.1016/S0022-5347(01)62073-1
37. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009;74(4):915-9. DOI:10.1016/j.urology.2009.05.033
38. Neveus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. DOI:10.1007/s00467-011-1762-8
39. Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты. РМЖ. Медицинское обозрение. 2021;5(5):273-9 [Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian)].
DOI:10.32364/2587-6821-2021-5-5-273-279
40. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;1:120-5 [Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;1:120-5 (In Russian)]. DOI:10.18565/urology.2021.1.120-125
41. Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты. Урологические ведомости. 2020;10(2):163-71 [Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St-Petersburg). 2020;10(2):163-71 (in Russian)]. DOI:10.17816/uroved102163-171
42. Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты. Клиническая геронтология. 2021;27(11-12):21-34 [Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21-34 (in Russian)].
DOI:10.26347/1607-2499202111-12021-034
43. Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10(10):CD012059. DOI:10.1002/14651858.CD012059.pub2
44. F-MELT® – система вспомогательных веществ для производства таблеток, диспергируемых в ротовой полости (ODT). Фармацевтическая отрасль. 2015;6(53):68-9 [F-MELT® – sistema vspomogatel'nykh veshchestv dlia proizvodstva tabletok, dispergiruemykh v rotovoi polosti (ODT). Farmatsevticheskaia otrasl'. 2015;6(53):68-9 (in Russian)].
45. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-60. DOI:10.1111/j.1742-1241.2007.01493.x
46. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction. J Urol. 2011;185(6):2308-13. DOI:10.1016/j.juro.2011.02.039
47. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-11. DOI:10.1177/0091270006291838
48. Vande Walle JGJ, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97(3):603-9. DOI:10.1111/j.1464-410X.2006.05999.x
49. Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235-42. DOI:10.1007/s00431-013-1992-9
50. Проспективное открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем®, таблетки подъязычные 240 мкг (ЗАО «Канонфарма продакшн», Россия), и Минирин®, таблетки подъязычные 240 мкг («Ферринг АГ», Швейцария) у здоровых добровольцев после однократного приема натощак. Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Ссылка активна на 01.11.2022 [Prospektivnoe otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem®, tabletki pod"iazychnye 240 mkg (ZAO «Kanonfarma prodakshn», Rossiia) i Minirin®, tabletki pod"iazychnye 240 mkg («Ferring AG», Shveitsariia) u zdorovykh dobrovol'tsev posle odnokratnogo priema natoshchak Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Accessed: 01.11.2022 (in Russian)].
51. Открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем® таблетки, 0,2 мг (ЗАО «Канонфарма Продакшн», Россия), и Минирин® таблетки, 0,2 мг («Ферринг АБ», Швеция). Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Ссылка активна на 01.11.2022 [Otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem® tabletki, 0,2 mg (ZAO «Kanonfarma Prodakshn», Rossiia), i Minirin® tabletki, 0,2 mg («Ferring AB», Shvetsiia). Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Accessed: 01.11.2022 (in Russian)].
________________________________________________
2. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol. 2001;165(6Pt. 1):1914-7. DOI:10.1097/00005392-200106000-00017
3. Guseva NB, Nikitin SS, Korsunskiy AA, et al. Results of a multicenter study on the diagnosis of nonmonosymptomatic enuresis in children in various regions of the Russian Federation. Pediatria. 2019;98(2):107-12 (in Russian). DOI:10.24110/0031-403X-2019-98-2-107-112
4. Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol. 2002;36(5):354-62. DOI:10.1080/003655902320783863
5. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. Int J Clin Pract. 2009;63(4):568-73. DOI:10.1111/j.1742-1241.2008.01974.x
6. Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int. 2004;93(3):341-5. DOI:10.1111/j.1464-410x.2003.04612.x
7. Nikitin SS, Guseva NB, Kolodyazhnaya AV, et al. Enuresis nocturna in children and adolescents: a review of contemporary literature and treatment perspectives using desmopressin. Pediatria n.a. GN. Speransky. 2020;99(3):265-70 (in Russian). DOI:10.24110/0031-403X-2020-99-3-265-270
8. Levine A. Enuresis in the navy. Am J Psychiatry. 1943;100:320-5.
9. Hirasing RA, van Leerdam FJ, Bolk-Bennink L, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 1997;31(6):533-6. DOI:10.3109/00365599709030657
10. Baek M, Park K, Lee HE, et al. Korean Children's Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: population based cross sectional study. J Korean Med Sci. 2013;28(7):1065-70. DOI:10.3346/jkms.2013.28.7.1065
11. Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315-20. DOI:10.1007/s00192-016-3099-0
12. Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Wh ere is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43(4):401-6. DOI:10.1097/WON.0000000000000234
13. Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down Syndrome. Neurourol Urodyn. 2017;36(6):1550-6. DOI:10.1002/nau.23146
14. Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8(3):217-22. DOI:10.1007/s11884-013-0193-8
15. Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9(2):84-9. DOI:10.1007/s11884-014-0237-8
16. Akhavizadegan H, Locke JA, Stothers L, Kavanagh A. A comprehensive review of adult enuresis. Can Urol Assoc J. 2018;13(8):282-7. DOI:10.5489/cuaj.5485
17. Rittig S, Lassen Schaumburg H, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179(6):2389-95. DOI:10.1016/j.juro.2008.01.171
18. Biryukova YeV, Shinkin MV. Central Diabetes Insipidus: Etiopathogenesis, Approaches to Diagnosis and Treatment. Effective Pharmacotherapy. 2021;17(26):38-48 (in Russian). DOI:10.33978/2307-3586-2021-17-26-38-48
19. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021-5. DOI:10.1097/01.ju.0000136203.76320.f6
20. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. DOI:10.1016/S0090-4295(02)02243-4
21. Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Expert Opin Pharmacother. 2018;19(3):291-8. DOI:10.1080/14656566.2018.1429406
22. Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23(2):175-82. DOI:10.1097/GME.0000000000000517
23. Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St-Petersburg). 2021;11(3):241-56 (in Russian). DOI:10.17816/uroved70710
24. Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35 (in Russian). DOI:10.17816/uroved108475
25. Abeygunasekera AM, Jayasinghe RJ, Duminda MT, et al. Significance of recent onset nocturnal enuresis in adult men: a prospective study. Ceylon Med J. 2004;49(3):79-81. DOI:10.4038/cmj.v49i3.3244
26. Madhu CK, Hashim H, Enki D, Drake MJ. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36(1):188-91. DOI:10.1002/nau.22912
27. Kuz'min IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyria: Dis. … d-ra med. nauk. Saint Petersburg, 2007 (in Russian).
28. D’Ancona CAL, de Moraes Lopes MHB, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31(5):634-6. DOI:10.1002/nau.21195
29. Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171(6Pt2):2595-8. DOI:10.1097/01.ju.0000112790.72612.0a
30. Katz EG, MacLachlan LS. Nocturnal Enuresis in the Adult. Curr Urol Rep. 2020;21(8):31. DOI:10.1007/s11934-020-00983-2
31. Lee D, Dillon BE, Lemack GE. Adult Onset Nocturnal Enuresis: Identifying Causes, Cofactors and Impact on Quality of Life. Low Urin Tract Symptoms. 2018;10(3):292-6. DOI:10.1111/luts.12183
32. Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. 2019;133:24-33. DOI:10.1016/j.urology.2019.09.022
33. Sinha R, Raut S. Management of nocturnal enuresis – myths and facts. World J Nephrol. 2016;5(4):328-38. DOI:10.5527/wjn.v5.i4.32
34. Läckgren G, Hjälmås K, van Gool J, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999;88(6):679-90. DOI:10.1080/08035259950169396
35. Yucel S, Kutlu O, Kukul E, Baykara M. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64(5):1020-5. DOI:10.1016/j.urology.2004.06.067
36. Vandersteen DR, Husmann DA. Treatment of primary nocturnal enuresis persisting into adulthood. J Urol. 1999;161(1):90-2. DOI:10.1016/S0022-5347(01)62073-1
37. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009;74(4):915-9. DOI:10.1016/j.urology.2009.05.033
38. Neveus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. DOI:10.1007/s00467-011-1762-8
39. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian).
DOI:10.32364/2587-6821-2021-5-5-273-279
40. Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;1:120-5 (In Russian). DOI:10.18565/urology.2021.1.120-125
41. Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St-Petersburg). 2020;10(2):163-71 (in Russian). DOI:10.17816/uroved102163-171
42. Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21-34 (in Russian).DOI:10.26347/1607-2499202111-12021-034
43. Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10(10):CD012059. DOI:10.1002/14651858.CD012059.pub2
44. F-MELT® – sistema vspomogatel'nykh veshchestv dlia proizvodstva tabletok, dispergiruemykh v rotovoi polosti (ODT). Farmatsevticheskaia otrasl'. 2015;6(53):68-9 (in Russian).
45. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-60. DOI:10.1111/j.1742-1241.2007.01493.x
46. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction. J Urol. 2011;185(6):2308-13. DOI:10.1016/j.juro.2011.02.039
47. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-11. DOI:10.1177/0091270006291838
48. Vande Walle JGJ, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97(3):603-9. DOI:10.1111/j.1464-410X.2006.05999.x
49. Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235-42. DOI:10.1007/s00431-013-1992-9
50. Prospektivnoe otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem®, tabletki pod"iazychnye 240 mkg (ZAO «Kanonfarma prodakshn», Rossiia) i Minirin®, tabletki pod"iazychnye 240 mkg («Ferring AG», Shveitsariia) u zdorovykh dobrovol'tsev posle odnokratnogo priema natoshchak Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Accessed: 01.11.2022 (in Russian).
51. Otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem® tabletki, 0,2 mg (ZAO «Kanonfarma Prodakshn», Rossiia), i Minirin® tabletki, 0,2 mg («Ferring AB», Shvetsiia). Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Accessed: 01.11.2022 (in Russian).
Авторы
И.В. Кузьмин*
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия
*kuzminigor@mail.ru
Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
*kuzminigor@mail.ru
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия
*kuzminigor@mail.ru
________________________________________________
Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
*kuzminigor@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.